Abstract
Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.
This is a preview of subscription content, log in via an institution to check access.
References
Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Int Organ Cancer Chronother Lancet 350:681–686
Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10(6):663–669
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947
Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, McFarland JG, Aster RH (2006) Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81:193–196
Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R (2004) FDA drug approval summaries: oxaliplatin. Oncologist 9:8–12
Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, Salama A (2005) Oxaliplatin-induced immune pancytopenia. Transfusion 45(5):704–708
Dold FG, Mitchell EP (2003) Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med 139(2):E156
Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A, Kalofonos HP (2004) Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage, and hemolysis. Oncology 67(2):179–182
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beg, M.S., Komrokji, R.S., Ahmed, K. et al. Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol 62, 925–927 (2008). https://doi.org/10.1007/s00280-007-0675-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-007-0675-5